PRIMARY STUDY
Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Key Findings: Data suggests a therapeutic potential (anti-dyskinesia) of Δ9-THCV. More specifically, THCV was able to delay the occurrence and to attenuate the magnitude of dyskinesia in an animal model of PD.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Spain
Year of Pub: 2020
Cannabinoids Studied: Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Injection
Cannabinoid Ratio: (THCV) 0 
Dosing Regimen: THCV was administered i.p. at 2 mg/kg
Treatment Duration: 2 weeks
Clinical Relevance: Data suggests a therapeutic potential (anti-dyskinesia) of Δ9-THCV. More specifically, THCV delayed the occurrence and attenuated the magnitude of dyskinesia in an animal model of PD.
Link to study
